HIV-2 Treatment in Mali and Drug Resistance Antiretroviral Profile

Main Article Content

Aboubacar Alassane Oumar
Drissa Katile
Ibrehima Guindo
Younoussa Sidibe
Paul M. Tulkens
Sounkalo Dao
Jean Ruelle
Benoit Mukadi-Kabamba


Aims: We evaluated different treatment regimens administered to patients infected with HIV-2 in Mali, and studied pol polymorphisms that may influence susceptibility to antiretrovirals.

Methodology: We collected 57 blood samples from HIV - 2 seropositive patients in health centers in Mali (Bamako, Segou and Sikasso), including 21 treated patients and 36 untreated patients. The confirmation of the serological status and the measurement of the viral load were carried out in Brussels. Genotypic analysis of protease, reverse transcriptase and integrase was then performed on specimens with detectable viral load. The search for ARV resistance mutations and polymorphism positions was performed in comparison with reference sequences.

Results: The most used treatment regimen was ZDV-3TC-LPV/ r.  Genotypic analysis of protease, reverse transcriptase and integrase was performed on 20 samples from patients with detectable viral load: 16 untreated patients and 4 treated patients. Seventy-five percent of the strains analyzed correspond to group A of HIV-2. In 2cas, mutations associated with resistance to the administered molecules were found. Three viral strains from untreated patients had NRTI or PI resistance mutations. In integrase, no mutation associated with resistance was observed.

Conclusion: The circulation of strains carrying resistance mutations to NRTIs and PIs has been observed in Mali.

HIV-2, antiretroviral therapy, efficacy, mutations, Mali.

Article Details

How to Cite
Oumar, A. A., Katile, D., Guindo, I., Sidibe, Y., Tulkens, P. M., Dao, S., Ruelle, J., & Mukadi-Kabamba, B. (2019). HIV-2 Treatment in Mali and Drug Resistance Antiretroviral Profile. International STD Research & Reviews, 8(1), 1-10.
Original Research Article


UNAIDS/WHO. Global Report.UNAIDS report on the global AIDS epidemic 2016. Geneva: UNAIDS. 2016;218.

Samake S, Traoré SM, Ba S, Dembele E, Diop M, Mariko S. Enquête Démogra-phique de la Santé au Mali, 2012-2013. In: CPS, ed. V. Bamako: ICF International. 2012;577.

Kashyap B, Gautam H, Bhalla P. Epidemiology and seroprevalence of human immuno deficiency virus type 2. Intervirology. 2011;54(3):151-5.

Abouya L, Coulibaly IM, Wiktor SZ, Coulibaly D, N'Kragbo M, N'Gbo A, et al. The Cote d'Ivoire national HIV counseling and testing program for tuberculosis patients: Implementation and analysis of epidemiologic data. AIDS. 1998;12(5): 505-12.

Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science. 1994; 265(5178):1587-90.

De Cock KM, Adjorlolo G, Ekpini E, Sibailly T, Kouadio J, Maran M, et al. Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic. JAMA. 1993;270(17): 2083-6.

Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: Implica-tions for treatment and postexposure prophylaxis. Antiviral Therapy. 2004;9(1): 57-65.

Rodes B, Sheldon J, Toro C, Jimenez V, Alvarez MA, Soriano V. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretro viral therapy. The Journal of Anti Microbial Chemotherapy. 2006;57(4): 709-13.

Gilleece Y, Chadwick DR, Breuer J, Hawkins D, Smit E, McCrae LX, et al. British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010. HIV Medicine. 2010; 11(10):611-9.

Damond F, Matheron S, Peytavin G, Campa P, Taieb A, Collin G, et al. Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen. Antiviral Therapy. 2004;9(4):635-6.

Pieniazek D, Ellenberger D, Janini LM, Ramos AC, Nkengasong J, Sassan-Morokro M, et al. Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast. AIDS Res Hum Retroviruses. 1999;15(6):603-8.

Ruelle J, Mukadi BK, Schutten M, Goubau P. Quantitative real-time PCR on Lightcycler for the detection of human immunodeficiency virus type 2 (HIV-2). J Virol Methods. 2004;117(1):67-74.

Colson P, Henry M, Tourres C, Lozachmeur D, Gallais H, Gastaut JA, et al. Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France. J Clin Microbiol. 2004;42(2):570-7.

Ruelle J, Roman F, Vandenbroucke AT, Lambert C, Fransen K, Echahidi F, et al. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database. BMC Infectious Diseases. 2008; 8:21.

Bercoff DP, Triqueneaux P, Lambert C, Oumar AA, Ternes AM, Dao S, et al. Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir. Retrovirology. 2010;7:98.

Adje C, Cheingsong R, Roels TH, Maurice C, Djomand G, Verbiest W, et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr. 2001;26(5):501-6.

Jallow S, Alabi A, Sarge-Njie R, Peterson K, Whittle H, Corrah T, et al. Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. J Clin Microbiol. 2009;47(7):2200-8.

Matheron S, Pueyo S, Damond F, Simon F, Lepretre A, Campa P, et al. Factors associated with clinical progression in HIV-2 infected-patients: The French ANRS cohort. AIDS. 2003;17(18):2593-601.

Benard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, et al. Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients. AIDS. 2009;23(9):1171-3.

Rodes B, Holguin A, Soriano V, Dourana M, Mansinho K, Antunes F, et al. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol. 2000;38(4): 1370-4.

Van der Ende ME, Guillon C, Boers PH, Ly TD, Gruters RA, Osterhaus AD, et al. Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr. 2000;25(1):11-8.

Jallow S, Kaye S, Alabi A, Aveika A, Sarge-Njie R, Sabally S, et al. Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia. AIDS. 2006;20(10):1455-8.

Turner D, Brenner B, Wainberg MA. Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1. Clinical and Diagnostic Laboratory Immunology. 2003;10(6):979-81.

Ruelle J, Sanou M, Liu HF, Vandenbroucke AT, Duquenne A, Goubau P. Genetic polymorphisms and resistance mutations of HIV type 2 in antiretroviral-naive patients in Burkina Faso. AIDS Res Hum Retroviruses. 2007;23(8):955-64.

Colson P, Henry M, Tivoli N, Gallais H, Gastaut JA, Moreau J, et al. Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France. J Med Virol. 2005;75(3):381-90.

Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. Journal of Molecular Biology. 1994;243(3):369-87.

Parreira R, Monteiro F, Padua E, Piedade J, Venenno T, Paixao MT, et al. Natural polymorphisms of HIV type 2 pol sequences from drug-naive individuals. AIDS Res Hum Retroviruses. 2006; 22(11):1178-82.

Gottlieb GS, Badiane NM, Hawes SE, Fortes L, Toure M, Ndour CT, et al. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: Implications for HIV-2 treatment in resouce-limited West Africa. Clin Infect Dis. 2009;48(4):476-83.

M'Barek NB, Audoly G, Raoult D, Gluschankof P. HIV-2 Protease resistance defined in yeast cells. Retrovirology. 2006; 3:58.

Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Benard A, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Anti-microbial Agents and Chemotherapy. 2008;52(4):1545-8.

Garrett N, Xu L, Smit E, Ferns B, El-Gadi S, Anderson J. Raltegravir treatment response in an HIV-2 infected patient: A case report. AIDS. 2008;22(9): 1091-2.

Xu L, Anderson J, Garrett N, Ferns B, Wildfire A, Cook P, et al. Dynamics of raltegravir resistance profile in an HIV type 2-infected patient. AIDS Res Hum Retroviruses. 2009;25(8):843-7.

Peterson K, Ruelle J, Vekemans M, Siegal FP, Deayton JR, Colebunders R. The role of raltegravir in the treatment of HIV-2 infections: Evidence from a case series. Antiviral Therapy. 2012;17(6):1097-100.

Matheron S, Descamps D, Gallien S, Besseghir A, Sellier P, Blum L, et al. First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: Phase 2 non-comparative trial (ANRS 159 HIV-2). Clin Infect Dis; 2018.

Zheng Y, Lambert C, Arendt V, Seguin-Devaux C. Virological and immunological outcomes of elvitegravir-based regimen in a treatment-naive HIV-2-infected patient. AIDS. 2014;28(15):2329-31.

Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Benard A, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. The Journal of Antimicrobial Chemotherapy. 2008;62(5):914-20.

Xu L, Anderson J, Ferns B, Cook P, Wildfire A, Workman J, et al. Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients. AIDS Res Hum Retroviruses. 2008;24(7): 1003-7.

Qiu X, Sokoll L, Yip P, Elliott DJ, Dua R, Mohr P, et al. Comparative evaluation of three FDA-approved HIV Ag/Ab combination tests using a genetically diverse HIV panel and diagnostic specimens. J Clin Virol. 2017; 92:62-8.